Penile Cancer (C60): 2000-2007
Age-Standardised Five-Year Relative Survival, Adults (Aged 15+), European Countries

All invasive, primary, malignant neoplasms except non-melanoma skin cancer were eligible for inclusion.

Data consists of both observed and predicted 5-year relative survival.

Where sufficient follow-up was not available for recently diagnosed patients the period approach was used to predict 5-year cohort survival.

For some European countries data is not available for one or both sexes.

95% LCL and 95% UCL are the 95% lower and upper confidence limits around the five-year relative survival.

Source: cruk.org/cancerstats

You are welcome to reuse this Cancer Research UK statistics content for your own work.

Credit us as authors by referencing Cancer Research UK as the primary source.

Suggested style: Cancer Research UK, full URL of the page, Accessed [month] [year].

<table>
<thead>
<tr>
<th>Sex</th>
<th>Slovakia</th>
<th>Latvia</th>
<th>Slovenia</th>
<th>Bulgaria</th>
<th>Lithuania</th>
<th>Croatia</th>
<th>Finland</th>
<th>Poland</th>
<th>Estonia</th>
<th>Czech Republic</th>
<th>Germany</th>
<th>Austria</th>
<th>Portugal</th>
<th>Switzerland</th>
<th>Scotland</th>
<th>Northern Ireland</th>
<th>Belgium</th>
<th>England Ireland</th>
<th>Spain</th>
<th>Sweden</th>
<th>France</th>
<th>Italy</th>
<th>Wales</th>
<th>Malta</th>
<th>The Netherlands</th>
<th>Denmark</th>
<th>Norway</th>
<th>Iceland</th>
</tr>
</thead>
<tbody>
<tr>
<td>Men</td>
<td>50.26</td>
<td>55.63</td>
<td>58.71</td>
<td>58.69</td>
<td>60.62</td>
<td>61.83</td>
<td>63.10</td>
<td>63.98</td>
<td>64.60</td>
<td>65.58</td>
<td>66.47</td>
<td>67.03</td>
<td>67.83</td>
<td>68.42</td>
<td>68.54</td>
<td>70.83</td>
<td>70.42</td>
<td>69.52</td>
<td>70.06</td>
<td>70.93</td>
<td>71.43</td>
<td>72.53</td>
<td>73.60</td>
<td>74.61</td>
<td>75.25</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>95% LCL</td>
<td>41.43</td>
<td>42.98</td>
<td>44.46</td>
<td>51.32</td>
<td>49.69</td>
<td>51.71</td>
<td>52.71</td>
<td>53.38</td>
<td>57.80</td>
<td>59.95</td>
<td>61.01</td>
<td>61.41</td>
<td>61.13</td>
<td>59.88</td>
<td>60.60</td>
<td>61.13</td>
<td>61.46</td>
<td>60.26</td>
<td>63.31</td>
<td>60.96</td>
<td>64.21</td>
<td>68.56</td>
<td>64.68</td>
<td>59.45</td>
<td>70.90</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>95% UCL</td>
<td>60.98</td>
<td>72.05</td>
<td>77.49</td>
<td>77.59</td>
<td>73.93</td>
<td>73.33</td>
<td>73.00</td>
<td>74.60</td>
<td>85.64</td>
<td>70.83</td>
<td>70.12</td>
<td>70.71</td>
<td>70.65</td>
<td>70.72</td>
<td>74.63</td>
<td>82.33</td>
<td>70.29</td>
<td>70.43</td>
<td>71.85</td>
<td>70.28</td>
<td>77.53</td>
<td>76.26</td>
<td>79.52</td>
<td>84.23</td>
<td>85.78</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(Prostate, primary malignant neoplasms except non-melanoma skin cancer were eligible for inclusion.

When sufficient follow-up was not available for recently diagnosed patients the period approach was used to predict 5-year cohort survival.

For some European countries data is not available for one or both sexes.

95% LCL and 95% UCL are the 95% lower and upper confidence limits around the five-year relative survival.

Credit us as authors by referencing Cancer Research UK as the primary source.

Suggested style: Cancer Research UK, full URL of the page, Accessed [month] [year].

Cancer Research UK